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E D I TO R I A L

Metabolomics: the final frontier?
Timothy D Veenstra*
The connection between genomics, proteomics and
metabolomics is evident in even the most simplistic of
scientific models. Genes give rise to mRNA. Proteins are
translated from mRNA and then proceed to carry out a
myriad of functions within the cell, including the metabolism of small molecules such as glucose and adenosine
triphosphate. Not that many years ago, scientists used to
study the ‘big 4’ biomolecules under the guise of genes,
transcripts, protein and metabolites. The last decade of
biomedical research, however, has been witness to the
growth of the ‘omics’ industries. Genomics, transcriptomics and proteomics have become core technologies
within almost every major academic or industrial
research program around the world. What was missing
was the final piece of the omics puzzle: metabolomics.

Mass spectrometry or nuclear magnetic
resonance?
From a technology perspective, metabolomics has come
along at precisely the right time. The two major technologies used to gather metabolomics data, mass spectrometry (MS) and nuclear magnetic resonance (NMR)
spectroscopy, have both reached fantastic heights of data
gathering capability [1,2]. Comparatively speaking, however, MS and NMR spectroscopy have their own specific
advantages and disadvantages when conducting metabolomic studies. The main advantage of MS is sensitivity, as
state-of-the-art mass spectrometers can detect analytes
routinely in the femtomolar to attomolar range. Coupling
MS with liquid chromatography (LC) or gas chromatography (GC) enables the measurement of hundreds of
individual species within a single sample. The combination of mass accuracy and real-time tandem MS available
with many mass spectrometers, along with increasingly
comprehensive databases, is making the identification of
these metabolites more routine. One of the major
weaknesses of MS in metabolomics is quantification. The
MS signal intensity of any compound is affected by the
type of sample preparation used and its molecular
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environment. Adding known amounts of internal isotopelabeled standards enables accurate quantification for
specific molecules; however, this strategy is impractical
for purely discovery-driven metabolomics research. Most
studies rely on comparing peak area or intensity to locate
differences in the relative abundance of specific
metabolites between samples. However, these measurements can suffer from a lack of accuracy and precision.
The major weaknesses of MS are the major strengths of
NMR spectroscopy. The peak area of a compound in the
NMR spectrum is directly related to the concentration of
specific nuclei (for example, 1H, 13C), making quantification of compounds in a complex mixture very precise.
A metabolite detected as being more abundant in a
specific sample can be identified either through the
resonance positions of its nuclei in the NMR spectrum,
or through the application of various pulse-sequences
such as total correlation spectroscopy, heteronuclear
single quantum coherence and heteronuclear multiple
bond correlation. Another underappreciated character of
NMR spectroscopy is its versatility for analyzing
metabolites in the liquid state (serum, urine and so on),
in intact tissues (for example, tumors) or in vivo.
Unfortunately, sensitivity, which is the major strength of
MS, is the major weakness of NMR spectroscopy.
Although cryogenically cooled probe technology, higher
field-strength superconducting magnets [3] and miniaturized radiofrequency coils [4] have increased sensitivity,
NMR spectroscopy is still orders of magnitude less
sensitive than MS.
While metabolomics is less mature than genomics and
proteomics, it is already making a major impact in a wide
variety of scientific areas, including newborn screening,
toxicology, drug discovery, food safety and biomarker
discovery (Figure 1). As with genomics and proteomics,
most of the pressure will be on metabolomics to find
biomarkers of diseases such as cancer. Investigators have
already shown the potential promise of metabolomics in
this area. For example, Sreekumar et al. [5] used LC-MS
and GC-MS to profile 42 tissue, 110 urine and 110 plasma
samples from patients affected with benign prostate
disease, clinically localized prostate disease and
metastatic disease. Not only were they able to distinguish
these three conditions based on the NMR data, but they
found that a specific metabolite, sarcosine, was highly
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Figure 1. Metabolomics of disease. Metabolomics technologies are making a major impact on a wide variety of scientific and clinical areas,
including newborn screening, toxicology, drug discovery, food safety and biomarker discovery. Please use the following link to access the
interactive version of this graphic [7].

increased in concentration during prostate cancer
progression to metastasis. This increased sarcosine level
could be detected non-invasively in urine. In an ovarian
cancer study, Dr Olivier Fiehn’s laboratory conducted a
metabolomics screening of 66 invasive ovarian carcinoma
tissues and 9 borderline tumors of the ovary [6]. Over 50
identified metabolites were shown to differ significantly
between the sample cohorts. Many of these metabolites
play a role in purine and pyrimidine metabolism, glycero
lipid metabolism and energy metabolism. The next
challenge with this study, as with every biomarker dis
covery study using omics technology, are to conduct
validation studies to determine if any of the metabolites
can be used to reliably diagnose the disease.

The future of metabolomics
Metabolomics has a unique opportunity to impact
discovery-driven science in a way that genomics, trans
criptomics and proteomics could not fully exploit.

Metabolomics is maturing at a time when the other three
omic technologies are much further advanced, and
therefore we now have a greater opportunity to integrate
metabolomics data with those obtained for the other ‘big
4’ biomolecules. If we go back to our simplistic model of
gene → transcript → protein → metabolite, our greatest
chance in finding truly useful disease biomarkers will be
studies that show correlation between biomolecules at all
four levels. With genomic, transcriptomic and proteomic
data collection and analysis further advanced, it seems
logical for any metabolomics discovery study to add
results from those whenever possible. Years of effort have
demonstrated, particularly in the fields of transcriptomics
and proteomics, that working in technological ‘silos’ is an
inefficient way to solve challenging biological problems.
A goal of the omic technologies is to be able to apply
them in a clinical setting to evaluate or monitor the
health status of patients. Of the two major technologies
utilized in metabolomics, MS is more likely than NMR
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spectroscopy to play a greater role in the clinic. MS is
already being applied routinely in clinical and diagnostic
laboratories. In its present role, the ability of MS to
directly measure a specific metabolite(s) in a biological
sample is employed using methods primarily built upon
isotope-dilution-MS. While most clinical MS assays are
conducted in reference laboratories, this scenario is likely
to change over the next few years as mass spectrometers
became a standard laboratory instrument and the
number of scientists familiar with this technology con
tinues to increase. While magnetic resonance imaging
(MRI) is widely used within hospitals, it is not the same
technology as the NMR spectroscopy described in this
editorial.
The ability to translate discovery into assays that can be
applied routinely within the clinic will have an enormous
impact on public health. In particular, the cry for diseasespecific biomarkers continues to be heard, as healthcare
professionals have been promised for over a decade that
omic technologies would meet this need. Can metabo
lomics be the science that finally conquers the biomarker
discovery challenge? On its own, it is likely to have no
more success than proteomics. On its own, it will flood
the literature with hundreds of studies that publish
hundreds of biomarkers that show potential but never
graduate to validation studies. However, integrating data
from genomic and/or proteomic studies that corroborate
metabolomics findings will provide the evidence needed
to confidently recognize those biomarkers that are worth
the resources required for validation. The hope is that
metabolomics can learn from the other omic techniques
and not repeat many of the same mistakes that have been
made in which a lot of data were collected but little
information was gleaned.
Abbreviations
GC, gas chromatography; LC, liquid chromatography; MS, mass spectrometry;
NMR, nuclear magnetic resonance.
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